Target-specific immunoPET Imaging of Breast Cancer
Development and Clinical Translation of immunoPET Imaging Probes for Breast Cancer
RenJi Hospital
200 participants
Sep 21, 2024
INTERVENTIONAL
Conditions
Summary
The aim of this study is to establish and optimize the Trop2/HER2-targeted PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in breast cancer will be evaluated.
Eligibility
Inclusion Criteria3
- Aged 18-75 years old and of female gender；
- Histologically confirmed diagnosis of breast cancer or suspected breast cancer by diagnostic imaging;
- Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.
Exclusion Criteria4
- Pregnancy；
- Severe hepatic and renal insufficiency;
- History of serious surgery in the last month;
- Allergic to antibody or single-domain antibody radiopharmaceuticals.
Interventions
Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-RT4. ImmunoPET/CT imaging will be acquired 1 hour after \[18F\]F-RESCA-RT4 injection.
Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-RB14. ImmunoPET/CT imaging will be acquired 1 hour after \[18F\]F-RESCA-RB14 injection.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06715826